Pembrolizumab associated hypereosinophilia in locally advanced triple-negative breast cancer
The advent of immunotherapy has revolutionized the therapeutic landscape of breast cancer.The immune checkpoint inhibitor drug, pembrolizumab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1), was recently approved by the Food and Drug Administration (FDA) as a neoadjuvant treatment in Liquorice combination with traditional ch